{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:27:12Z","timestamp":1767677232847,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00520-019-05280-4","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T07:02:51Z","timestamp":1578466971000},"page":"2095-2103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting\u2014a systematic review and meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-8624","authenticated-orcid":false,"given":"Ronald","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Sodhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"5280_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00520-006-0176-9","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:491\u2013503","journal-title":"Support Care Cancer"},{"key":"5280_CR2","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478","journal-title":"J Clin Oncol"},{"key":"5280_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/cncr.21222","volume":"104","author":"RJ Gralla","year":"2005","unstructured":"Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5-HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104:864\u2013868","journal-title":"Cancer"},{"key":"5280_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00520-015-3000-6","volume":"24","author":"R Chow","year":"2016","unstructured":"Chow R, Chiu L, Navari R, Passik S, Chiu N, Popovic M, Lam H, Pasetka M, Chow E, DeAngelis C (2016) Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and phase II studies: a systematic review. Support Care Cancer 24:1001\u20131008","journal-title":"Support Care Cancer"},{"key":"5280_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1517\/14656560902731894","volume":"10","author":"RM Navari","year":"2009","unstructured":"Navari RM (2009) Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 10:629\u2013644","journal-title":"Expert Opin Pharmacother"},{"key":"5280_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JGO.2015.002477","volume":"3","author":"B Gyawali","year":"2016","unstructured":"Gyawali B, Poudyal B, Iddawela M (2016) Cheaper options in the prevention of chemotherapy-induced nausea and vomiting. J Glob Oncol 3:145\u2013153","journal-title":"J Glob Oncol"},{"key":"5280_CR7","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-018-4237-7","volume":"26","author":"R Chow","year":"2016","unstructured":"Chow R, Warr DG, Navari RM et al (2016) Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer 26:2519\u20132549","journal-title":"Support Care Cancer"},{"key":"5280_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.critrevonc.2018.02.001","volume":"124","author":"M Di Maio","year":"2018","unstructured":"Di Maio M, Baratelli C, Bironzo P et al (2018) Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol 124:21\u201328","journal-title":"Crit Rev Oncol Hematol"},{"key":"5280_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21037\/jhmhp.2018.04.05","volume":"2","author":"R Chow","year":"2018","unstructured":"Chow R, Warr DG, Navari RM et al (2018) Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. J Hosp Manag Health Policy 2:25","journal-title":"J Hosp Manag Health Policy"},{"key":"5280_CR10","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381\u20132392","journal-title":"Support Care Cancer"},{"key":"5280_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.critrevonc.2017.02.017","volume":"112","author":"J Yoodee","year":"2017","unstructured":"Yoodee J, Permsuwan U, Nimworapan M (2017) Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Crit Rev Oncol Hematol 112:113\u2013125","journal-title":"Crit Rev Oncol Hematol"},{"key":"5280_CR12","volume":"9","author":"A Sutherland","year":"2018","unstructured":"Sutherland A, Naessens K, Plugge E et al (2018) Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev 9:CD012555","journal-title":"Cochrane Database Syst Rev"},{"key":"5280_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro D, Falcone J, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radio-receptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396","journal-title":"Neuropsychopharmacology"},{"key":"5280_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1126\/science.1115740","volume":"310","author":"MD Van Sickle","year":"2005","unstructured":"Van Sickle MD, Duncan M, Kingsley PJ et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329\u2013332","journal-title":"Science"},{"key":"5280_CR15","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663","journal-title":"Support Care Cancer"},{"key":"5280_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195","journal-title":"J Support Oncol"},{"issue":"Suppl 3","key":"5280_CR17","first-page":"1","volume":"5","author":"MD Slatin","year":"2007","unstructured":"Slatin MD (2007) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 5(Suppl 3):1\u20139","journal-title":"J Support Oncol"},{"key":"5280_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00520-001-0335-y","volume":"10","author":"JM Koeller","year":"2002","unstructured":"Koeller JM, Aapro MS, Gralla RJ et al (2002) Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 10:517\u2013518","journal-title":"Support Care Cancer"},{"key":"5280_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-91-6-819","volume":"91","author":"AE Chang","year":"1979","unstructured":"Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Simon RM, Rosenberg SA (1979) Delta-9-Tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. Ann Intern Med 91:819\u2013824","journal-title":"Ann Intern Med"},{"key":"5280_CR20","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4","volume":"47","author":"AE Chang","year":"1981","unstructured":"Chang AE, Shiling DJ, Stilman RC et al (1981) A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving Adriamycin and Cytoxan chemotherapy. Cancer 47:1746\u20131781","journal-title":"Cancer"},{"key":"5280_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/0277-5379(88)90300-8","volume":"24","author":"D Cunningham","year":"1988","unstructured":"Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Soukop M, Kaye SB (1988) A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24:685\u2013689","journal-title":"Eur J Cancer Clin Oncol"},{"key":"5280_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","volume":"91","author":"S Frytak","year":"1979","unstructured":"Frytak S, Moertel CG, O\u2019Fallon JR et al (1979) Delta-9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. Ann Intern Med 91:825\u2013830","journal-title":"Ann Intern Med"},{"key":"5280_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1185\/030079907X167525","volume":"23","author":"E Meiri","year":"2007","unstructured":"Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23:533\u2013543","journal-title":"Curr Med Res Opin"},{"key":"5280_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/BF01728184","volume":"64","author":"N Niederle","year":"1986","unstructured":"Niederle N, Schutte J, Schmidt CG (1986) Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 64:362\u2013365","journal-title":"Klin Wochenschr"},{"key":"5280_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJM197510162931603","volume":"293","author":"SE Sallan","year":"1975","unstructured":"Sallan SE, Zinberg NF, Frei E (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293:795\u2013797","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05280-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:36:41Z","timestamp":1609979801000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05280-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5280"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05280-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"23 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}